Video

Sickle cell disease guidelines release set for early 2019


 

FROM ASH 2018

– State-of-the-art guidelines for treating sickle cell disease are actively being developed and could be released as early as the spring of 2019, according to Robert Liem, MD, chair of the American Society of Hematology coordination panel for the initiative.

The new clinical practice recommendations will expand on 2014 guidelines published by the National Heart, Lung, and Blood Institute in a way that will help both hematologists and nonhematologists who take care of patients with sickle cell disease, Dr. Liem said in a video interview at the annual meeting of the American Society of Hematology.

Five different guidelines are under development to cover different aspects of acute and chronic complications of sickle cell disease, including pain, cardiopulmonary and kidney disease, cerebrovascular disease, transfusion support, and stem cell transplantation.


Watch the video to learn more about the guideline effort from the perspective of Dr. Liem, who is also the director of the Comprehensive Sickle Cell Program at the Ann & Robert H. Lurie Children’s Hospital of Chicago.

Recommended Reading

In Ghana, SCD research is meeting patients on home turf
MDedge Internal Medicine
Crizanlizumab relieves sickle cell crises across subgroups
MDedge Internal Medicine
FDA approves DNA-based blood type test
MDedge Internal Medicine
Sickle cell disease gene therapy seen advancing
MDedge Internal Medicine
Primary care needs pile up for sickle cell patients
MDedge Internal Medicine
Researchers seek more sickle cell drug research
MDedge Internal Medicine
Flipping the fetal hemoglobin switch reverses sickle cell symptoms
MDedge Internal Medicine
Sickle cell disease phenotype reversed by gene therapy
MDedge Internal Medicine
New treatments promise sickle cell “cure” for all ages
MDedge Internal Medicine
Opioids appear safe for sickle cell pain
MDedge Internal Medicine